Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CuraGen and TopoTarget initiate belinostat Phase II cancer trial
This trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for belinostat. The primary objective of the study is to
This trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for belinostat. The primary objective of the study is to
The Multiple Myeloma Research Consortium (MMRC) collaboration is evaluating the preclinical activity of SNS-032 in multiple myeloma-relevant models and in primary disease tissue, extending non-clinical studies performed by
The participants in this clinical trial were randomized 1:1 in the treatment and placebo arms of the study titled, “randomized, single-blind, placebo-controlled study to evaluate the safety of
Genzyme believes that Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience, while reducing the overall cost of therapy associated with multiple injections and offering a
The primary objective of the Phase II trials was to evaluate the safety and tolerability of treatment with Amigal. The secondary goal was to evaluate certain so-called pharmacodynamic
The Valstar-specific issues that caused the 2002 withdrawal of the product from the market have been reportedly resolved. However, during a recent FDA pre-approval inspection of the company’s
As part of the settlement an undisclosed cash consideration was paid by Ventana to Qiagen and Qiagen acknowledges that pursuant to an asset purchase agreement dated September 23,
Under the revised agreement, Altus regains control of its ALTU-238 assets and Genentech has agreed to provide, for a limited term, supplies of human growth hormone for future
The Ministry of Health and Medical Education (MOHME) will purchase 20,000 vials of Haemate P in 500 IU vials in the first year of launch, administering it in
James Karis, president and CEO of Entelos, said: “The deal reinforces Entelos’s stated strategy to enable proprietary drug development, particularly in chronic disease areas where multiple drugs, treatment